Harnessing the Power of the Immune System
T cells are critical to the immune system’s ability to detect and kill cancer cells. However, the immune system is unable to kill cancer cells when tumor-specific T cells are deficient in number, are unable to function properly or fail to recognize cancer as foreign to the body.
We are developing novel T cell-based cancer immunotherapies intended to directly address this problem. Our engineered cell therapy technology is designed to harness the power of a patient’s own immune system to effectively target and kill cancer cells.
Collect patient's white blood cells
Isolate and activate T cells
Grow and expand number of T cells
Infuse patient with engineered T cells
One Mission, Two Platforms
We are developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T cell receptor (TCR), depending on the type of cancer. Our dual platform has the potential to address both hematological and solid tumor cancers.
The Science of CAR T
Chimeric Antigen Receptor (CAR)
CARs are engineered proteins composed of two distinct functional components. The first consists of an antibody fragment or target binding domain that allows CARs to recognize targets that are present on the surface of cancer cells. The second provides signals that rapidly and powerfully activate the T cell to attack and kill cancer cells. We are developing multiple CAR product candidates, including KTE-C19, while continuing to innovate the next generation of CAR-engineered T cells to achieve even greater results.
The Science of CAR T
T Cell Receptor (TCR)
TCRs are proteins that allow T cells to identify cancer targets presented on the surface of cancer cells or inside cancer cells. Endogenous TCRs that are specific to a cancer can be isolated and then engineered into a large number of T cells that recognize and attack various types of solid and hematologic cancers. Kite, in collaboration with its partners, is currently advancing several TCR-engineered T cell programs that target cancer-specific proteins such as cancer testis antigens, viral antigens and neo antigens. Kite is also leveraging its proprietary TCR-GENErator™ discovery platform for rapid, high-throughput identification of TCR-based product candidates.